The most widely accepted concept for the reduction in heart failure hospitalizations is attributed to the reduction in the effective circulating volume owing to increased diuresis related to glycosuria as well as the natriuresis, with SGLT2 inhibitor use; however, this explanation is believed to be incomplete as these effects are transient with a return towards baseline within a few days due to re‐establishment of the sodium‐water balance and studies suggesting no significant reduction in urinary excretion.10, 11. The gene discussed is SLC5A2; the disease is heart failure.